Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

This is a trial designed to assess the safety and tolerability of multiple-dose
administrations of aripiprazole intramuscular (IM) depot in the deltoid muscle in adult
subjects with schizophrenia. The trial consists of a 113 day treatment period with a 28 day
followup. The trial population will include male and female subjects between 18 and 64 years
(inclusive), with a current diagnosis of schizophrenia as defined by DSM-IV-TR criteria and
a prior history of tolerating aripiprazole per investigator's judgement.

Inclusion Criteria:

- Male and femlae individuals between 18 and 64 years, inclusive, at the time of
informed consent.

- Prior history of tolerating aripiprazole per investigator's judgement.

Exclusion Criteria:

- Subjects who have met DMSV-IV-TR criteria for substance dependence within the past
180 days.

- Subjects who use more than one antipsychotic medication at screening.

- Use of any CYP2D6 and CYP3A4 inhibitors, or CYP3A4 inducers within 14 days prior to
dosing and for the duration of the trial.

- Subjects who participated in any clinical trial involving a psychotropic medication
within 1 month prior to enrollment.

- Subjects currently in an acute relaps of schizophreniz.

- Subjects with a current DSMV-IV-TR diagnosis other than schizophrenia.

- Subjects who are considered treatment-resistant to antipsychotic medications.